Intervention: T-DXd combined with immune checkpoint inhibitor
Found 4 matching trials
A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer
PHASE2
This is a prospective, open-label, multicenter, single-arm clinical study d...
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
PHASE3
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + r...